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Abstract
Purpose To determine the incidence of Herpes zoster in
patients with one of 17 speciﬁc underlying diseases com-
pared with that in patients with other underlying diseases.
Methods We conducted a retrospective hospital-based
cohort study using data from patients’ electronic medical
records for the period 2001–2007 of the Kitano Hospital
Research Database. These analyses included 55,492
patients with one of 17 underlying diseases, which were
those reported as related to the contraction of Herpes
zoster. Of these, 769 patients contracted Herpes zoster. The
main outcome measure was the clinical diagnosis of Her-
pes zoster.
Results The adjusted hazard ratios (95% conﬁdence
interval) for Herpes zoster in patients with the 17 diseases
were compared with other patients, with the follow-
ing results: brain tumor [3.84 (2.51–5.88)], lung cancer
[2.28 (1.61–3.22)], breast cancer [2.41 (1.52–3.82)],
esophageal cancer [4.19 (2.16–8.11)], gastric cancer [1.95
(1.39–2.72)], colorectal cancer [1.85 (1.33–2.56)], gyne-
cologic cancer [3.45 (2.08–5.70)], malignant lymphoma
[8.23 (6.53–10.38)], systemic lupus erythematosus [3.90
(2.66–5.70)], rheumatoid arthritis [2.00 (1.60–2.50)], dia-
betes mellitus [2.44 (2.10–2.85)], hypertension [2.04
(1.75–2.38)], renal failure [2.14 (1.65–2.79)], and disk
hernia [2.18 (1.52–3.13)].
Conclusions Patients with diabetes mellitus, renal failure,
and malignancies have a 1.8–8.4-fold higher risk of a
Herpes zoster event than patients with other diseases.
Future studies should investigate alteration of the immune
system in the underlying diseases and approaches for
Herpes zoster prevention.
Keywords Herpes zoster  Underlying disease 
Incidence  Risk
Introduction
Herpes zoster (HZ), which occurs at all ages, is a clinical
manifestation of the reactivation of the varicella-zoster virus
(VZV). Reactivation of latent infection results from declin-
ing speciﬁc cell-mediated immunity [1], which subsequently
engenders HZ [1–3]. The estimated lifetime risk of devel-
oping HZ in those exposed to varicella is 10–30%. The
incidence of HZ per 1,000 person-years ranges between 1
a n d5[ 4, 5]. Associations between the incidence of HZ and
malignancies such as lymphoma, human immunodeﬁciency
virus (HIV) disease, cancer, autoimmune disease, systemic
lupus erythematosus (SLE) [6–8], rheumatoid arthritis (RA)
[9–11], psychological disease [12], and major depression
[13] have been recognized. Diabetes mellitus (DM) was
recently reported as a risk factor for HZ [14]. Disseminated
zoster in elderly patients with hypertension and congestive
heart failure was also reported recently [15]. Nevertheless, it
remains unknown whether the risk of developing HZ
increases in patients with common underlying diseases that
might alter immune functions. Through this single hospital-
based study at Kitano Hospital in Osaka, Japan, we inves-
tigated the respective contributions of various diseases to the
incidence of developing HZ.
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Study design
A hospital-based retrospective cohort study was conducted
based on the database of the Tazuke Kofukai Medical
Research Institute, Kitano Hospital.
Data sources
Data were collected from adult patients with histories of 1
of 17 speciﬁc underlying diseases, who had visited the
emergency departments, outpatient clinics, and inpatient
departments. This hospital, located in the center of the
Kita ward in Osaka, plays a central role in community
health care. In the Japanese system, patients are free to
consult any provider—primary care or specialist—at any
time [16]. The patients usually visit the same hospital
even when they present only mild clinical symptoms and
signs. The study period was September 1, 2001 to
December 31, 2007.
Inpatient and outpatient records were reviewed. They
included data of patient age, sex, and underlying comor-
bidity, date of the ﬁrst outpatient visit, admission and
discharge, vital status at discharge, and outpatient and
inpatient diagnoses (ICD-10-CM codes). Medical records
of all patients were also reviewed for patient data and
clinical characteristics from the day of diagnosis of the
selected diseases to the day of occurrence of HZ, the last
day of follow-up, death, or end of data abstraction
(December 31, 2007). The institutional ethics committee
provided approval for the retrospective review of the
patient data.
Cohort selection
The cohort included patients who had ICD-10-CM code
diagnoses of the underlying diseases of interest. To assist in
estimating associations between the underlying diseases
and HZ, we selected diseases that had been reported pre-
viously to be related with HZ (i.e., eight malignant diseases
of brain tumor, lung cancer, breast cancer, esophageal
cancer, gastric cancer, colorectal cancer, gynecologic
cancer, and malignant lymphoma; three autoimmune dis-
eases of SLE, RA, Sjo ¨gren’s syndrome; and one psychiatric
disease of depression) or might plausibly be associated
with VZV infection or with impaired immunological
responses to VZV (one metabolic disease of DM, one
cardiovascular disease of hypertension, and one renal dis-
order of renal failure). Patients with diseases that had no
plausible association with HZ (e.g., one osteoskeletal dis-
ease; disk hernia, one ocular disease; cataract) were
selected as controls.
This study evaluated 17 diseases. Patients with one of
those 17 diseases were enrolled at the ﬁrst diagnosis
recorded in the patient ﬁle. Diseases of enrolled patients
were as follows (ICD-10-CM codes): cancer—brain tumor
(C719, D320, 330–332, 420, 430–432), lung cancer (C330,
340–343, 348–349), breast cancer (C501–505, 509, 792,
795), esophageal cancer (C150–155, 159), gastric cancer
(C161–164, 169), colorectal cancer (C180–190, 200),
gynecologic cancer (C538–539, 541, 542, 549, 550, 560),
and malignant lymphoma (C810–813, 819–822, 829–844,
851, 857, 859); autoimmune diseases—SLE (M320–321,
329), RA (M0530, 0590, 0600, 0690–0697), and Sjo ¨-
gren’s syndrome (M350); metabolic disease—DM
(E100–107, 109–117, 119, 120, 130–137, 139–146, 149);
cardiovascular disease—hypertension (I100, 110,
119,120, 129, 39, 141, 150-152, 159); renal disorder—
renal failure (N179, 180, 189,190, 990); osteoskeletal
disease—disk hernia (M502, 512); ocular disease—cata-
ract (H250–252, 258–264, 268–269); and mood disor-
der—depression (F030, 063, 107, 191, 197, 204, 251,
313–315, 318–323, 328–334, 339, 341, 348, 349, 381,
412, 432, 530, 920).
Outcome
The study endpoint was the ﬁrst occurrence of HZ. Incident
cases were deﬁned as the ﬁrst incidence of HZ based on the
record of a doctor’s diagnosis and identiﬁed from inpatient
and outpatient encounters that included ICD-10-CM code
B020–023, 027–029 (HZ). For all analyses, incident cases
of HZ occurring after the patient’s cohort entry date were
ascertained using the ﬁrst HZ diagnosis recorded in the
patient ﬁle in the Kitano Hospital database. Patients who
had HZ at any time prior to the diagnosis of the 17
underlying diseases and those with recurrent HZ were
excluded. The incidence of HZ was calculated as the
number of events per 1,000 patient-years.
Statistical analysis
The Kaplan–Meier estimation, deﬁned as the base hazard
function for the acquisition of HZ along with age, was used
to determine the cumulative HZ-free survival rate inci-
dence during the ﬁrst 6 years of underlying disease. The
Cox proportional hazards models were used to compare the
rates of HZ among patients with each of the 17 diseases
and to determine the risks of developing HZ. The hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) were
estimated after adjustment for age and other comorbidities.
Statistical signiﬁcance was inferred for p value\0.05. All
statistical tests were two-sided and were performed using a
statistical software package (Stata ver. 10 for Windows;
StataCorp LP, College Station, TX).
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123Results
Study population and patient characteristics
The full cohort included 55,492 patients who had one or
more of the 17 diseases (with or without HZ) at Kitano
Hospital: 25,998 (47%) of the patients were male and
29,494 (53%) were female. The mean age at diagnosis was
60.1 years (range 20–103 years). The characteristics of the
patients are described in Table 1.
HZ outcomes
As noted, 769 (1.4%) of the 55,492 patients subsequently
developed HZ during the 6-year study period, of which 373
(49%) were male and 396 (51%) were female. The annu-
alized incidence rate of HZ was 2.2 episodes per 1,000
patient-years. The age-related changes of the incidence of
HZ are shown in Table 1. Precise descriptive characteris-
tics of the cohort are presented in Table 2.
For univariate analysis, the Kaplan–Meier hazard func-
tion for the acquisition of HZ in the patients with under-
lying diseases is portrayed in Fig. 1. During the 6.3 years
of observation, a log-rank test showed that patients with
Table 1 Descriptive characteristics of the study population: of
55,492 patients with one of 17 speciﬁc diseases, 769 patients subse-
quently developed Herpes zoster
Disease All subjects
HZ (?)H Z ( -)
All subjects 769 54,723 55,492
Mean age (SD) 63.95 (13.75) 60.03 (16.55) 60.09 (16.52)
Sex
Male 373 25,625 25,998
Mean age (SD) 64.13 (12.59) 59.54 (15.93) 59.61 (15.90)
Female 396 29,098 29,494
Mean age (SD) 63.79 (14.77) 60.47 (17.06) 60.51 (17.03)
Age group (years)
20–29 22 3,433 3,455
30–39 30 4,288 4,318
40–49 51 4,979 5,030
50–59 149 10,624 10,773
60–69 231 14,570 14,801
70–79 222 12,638 12,860
80–89 60 3,823 3,883
90–99 4 366 370
C100 0 2 2
Table 2 Characteristics of 55,492 patients with 17 underlying diseases at Kitano Hospital
Disease Total HZ (-)H Z ( ?) Age of total
subjects
Age of HZ
patients
Gender
(number
of subjects)
Gender
(number
of HZ patients)
Duration
to HZ*
Mean SD Mean SD Male Female Male Female Mean SD
Brain tumor 1,393 1,371 22 54.15 18.21 65.85 9.87 624 769 7 15 2.09 2.01
Lung cancer 1,410 1,375 35 67.71 11.95 68.00 10.08 906 504 26 9 1.08 1.15
Breast cancer 1,469 1,450 19 57.90 13.26 61.12 13.45 8 1,461 0 19 1.40 1.23
Esophageal cancer 307 298 9 65.85 9.37 64.93 8.80 240 67 7 2 1.29 1.51
Gastric cancer 1,777 1,740 37 66.35 11.70 66.32 9.56 1,186 591 24 13 1.90 1.66
Colorectal cancer 1,924 1,885 39 66.14 12.22 71.02 10.12 1,110 814 24 15 1.78 1.73
Gynecologic cancer 1,124 1,108 16 52.76 15.33 55.29 10.13 1 1,123 0 16 1.28 1.37
Malignant lymphoma 1,917 1,824 93 48.31 23.26 56.88 16.10 912 1,005 44 49 1.09 1.14
Systemic lupus erythematosus 1,077 1,039 38 48.23 19.29 51.18 20.88 252 825 10 28 1.82 1.76
Rheumatoid arthritis 6,714 6,604 110 55.60 17.36 62.90 14.49 2,825 3,889 36 74 1.71 1.57
Sjo ¨gren’s syndrome 1,147 1,131 16 55.83 16.06 57.35 18.52 176 971 3 13 1.44 1.68
Diabetes mellitus 15,790 15,517 273 63.06 13.23 64.79 12.53 9,248 6,542 152 121 1.69 1.57
Hypertension 15,975 15,693 282 64.88 13.59 67.04 12.03 8,546 7,429 147 135 1.70 1.60
Renal failure 2,577 2,504 73 65.98 14.94 66.88 12.10 1,543 1,034 43 30 1.52 1.57
Disc hernia 2,804 2,773 31 50.36 17.13 63.81 13.57 1,591 1,213 14 17 2.09 1.72
Cataract 18,247 18,049 198 68.45 10.84 69.03 8.48 7,908 10,339 94 104 1.65 1.58
Depression 6,803 6,761 42 52.00 18.86 64.91 12.89 2,666 4,137 15 27 1.34 1.44
* Time in years from underlying disease to HZ: period from the onset of the underlying disease to the time of the ﬁrst development of HZ
Risk of Herpes zoster in patients with underlying diseases 539
123one of the following 16 diseases had signiﬁcantly lower
survival rates than that of the cohort without these diseases:
brain tumor, lung cancer, breast cancer, esophageal cancer,
gastric cancer, colorectal cancer, gynecologic cancer,
malignant lymphoma, SLE, RA, Sjo ¨gren’s syndrome, DM,
hypertension, renal failure, disk hernia, and cataract.
Patients with depression did not have signiﬁcantly different
survival rates from those of disease-free controls.
Potential risk factors for HZ
The associations between the underlying diseases and
subsequent HZ events were determined using Cox pro-
portional hazards models. For univariate analysis, 15 dis-
eases were independently associated with increased risk for
subsequent HZ events (Table 3). For multivariate analysis,
the Cox proportional hazard models adjusted for age
showed that the following 14 diseases signiﬁcantly
increased the risk of developing HZ: brain tumor, lung
cancer, breast cancer, esophageal cancer, gastric cancer,
colorectal cancer, gynecologic cancer, malignant lym-
phoma, SLE, RA, DM, hypertension, renal failure, and disk
hernia. The remaining three diseases—Sjo ¨gren’s syn-
drome, cataract, and depression—were not associated with
the risk of HZ (Table 3). Female gender had a signiﬁcant
inverse association with HZ in the univariate analysis, but
it was not associated with subsequent HZ events in the
multivariate analysis.
Discussion
The results showed that patients who had one of the 14
underlying diseases, i.e., brain tumor, lung cancer, breast
cancer, esophageal cancer, gastric cancer, colorectal can-
cer, gynecologic cancer, malignant lymphoma, SLE, RA,
DM, hypertension, renal failure, and disk hernia, displayed
a 1.8–8.4-fold increased risk of HZ events compared to
patients with none of these diseases in this cohort. No
signiﬁcantly higher risk of HZ was found for female
patients than for male patients.
Our study has several limitations. First, patients with
underlying diseases were not compared with healthy indi-
viduals. A prospective cohort study to compare patients with
theseunderlyingdiseasestohealthycontrolswouldrequirean
expensive large-scale research project, necessitating several
years and a larger patient cohort. The second limitation was
the observational period. Patients did not necessarily visit the
same hospital after the development of HZ. We examined
patients who had contracted HZ and visited the outpatient
department as outpatients. Patients who had been treated in a
hospital for other diseases would usually return to the outpa-
tient department of the same hospital in the Japanese health
servicesystem.Thisrestrictionmightimprovetheaccuracyof
the diagnosis and follow-up data.
It is known that VZV can be reactivated after many
years and that it can induce HZ [17, 18]. People with
suppressed cell-mediated immunity caused by immuno-
suppressive disorders or therapies are well described as
having a higher risk of developing zoster. In fact, advanced
age [17, 18], trauma [18], stress [18], and immune sup-
pression are important risk factors of reactivation. Patients
with medical conditions indicating compromised immunity
have increased risk of developing HZ. Prior studies have
identiﬁed immunosuppressive therapy (including cortico-
steroids), organ transplantation, malignancy [19–22], HIV
disease [22–25], autoimmune disease, SLE [8, 21], and RA
[9, 10, 19, 21] as HZ risk factors. Previous studies have
yielded controversial results: some studies have shown DM
to be a risk factor for HZ [14, 26], whereas others have not
[27]. Adults with major depression have lower VZV-spe-
ciﬁc cellular immunity than controls, but they were not
examined for the consequent risk of HZ [13]. A slight but
insigniﬁcant association was found between HZ and
depression.
Certain comorbidities were also independent risk factors
for HZ in patients treated with immunosuppressive agents.
Lupus nephritis was a risk factor for HZ in patients with
SLE [21]. Renal dysfunction was a risk factor for HZ
patients with Wegener’s granulomatosis [28]. Several
medical conditions (malignancy, chronic lung disease,
renal failure, and liver disease) were independent risk
factors for HZ in patients with RA [11]. The results show
that patients with one of 14 underlying diseases, including
malignancy, autoimmune diseases, metabolic disease,
hypertension, renal failure, and disk hernia, had a higher
risk for HZ than patients with any other diagnosis. The
results of this study showed that patients with underlying
diseases have a higher risk of developing HZ, which might
be attributable to the progressive decline in the VZV-
speciﬁc cell-mediated immunity that occurs in conditions
that compromise immune function. We have recently
reported that cell-mediated immunity to VZV in DM
patients was signiﬁcantly lower than in healthy individ-
uals [29]. Other comorbidities might affect VZV-speciﬁc
immunity. Major depression is associated with a marked
decline in VZV-speciﬁc cellular immunity in patients
Fig. 1 Patients with depression showed no signiﬁcantly lower event-
free survival rate than the cohort without the disease (17). Patients
with one of the other 16 underlying diseases showed signiﬁcantly
lower event-free survival rate than the cohort without the index
disease (1–16). Kaplan–Meier plots of Herpes zoster event-free
survival over 6 years of follow-up after the time of the ﬁrst diagnosis
of underlying disease in 2001–2007 at the Kitano Hospital Tazuke
Kofukai Medical Research Institute. The x-axis shows age. The y-axis
shows probability. p-values are derived using the log-rank test
c
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123older than 60 years [13]. A recent population-based study
demonstrated that affective psychoses increased the risk
of developing HZ by 1.34-fold in patients younger than
60 years of age [12]. Depression was not associated with
subsequent HZ events in this study, probably because no
investigation was conducted according to age. Disk her-
nia patients showed a higher risk for HZ than we
expected as a control, probably because most were
treated surgically.
The live attenuated vaccine to prevent HZ in adults
aged C60 years was approved by the US Food and Drug
Administration (FDA) and was recommended by the
Advisory Committee for Immunization Practices (ACIP).
It might reduce the burden of HZ and its complications
greatly, including postherpetic neuralgia, in this age
group. The use of a live attenuated varicella vaccine to
prevent HZ would be contraindicated in persons who
have impaired cellular immunity: they might develop
symptomatic, progressive infection with vaccine virus
[30]. An inactivated varicella vaccine might be useful
for the early reconstitution of adaptive immunity to
VZV after hematopoietic cell transplantation. The results
of this study suggest that patients with underlying
diseases should be targeted for vaccination under the
monitoring of both the safety and immunogenicity of the
vaccine.
Conclusions
Our study showed that patients with certain underlying
diseases have a 1.8–8.4-fold heightened risk of develop-
ing Herpes zoster (HZ) compared to other patients.
Although the risk of HZ in those patients was not com-
pared to that in healthy individuals, the results revealed a
signiﬁcantly heightened risk among patients with meta-
bolic disease, cardiovascular disease, and renal failure, as
well as those with malignant diseases and autoimmune
diseases.
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Table 3 Risk of Herpes zoster in the comparison cohort, 2001–2007 (n = 55,492)
Disease or status 1,000
person-
years
Disease Comparison patients Univariate Multivariate
HZ (?)H Z ( -)H Z ( ?)H Z ( -) Hazard ratio (95%
conﬁdence interval)
p-value Hazard ratio (95%
conﬁdence interval)
p-value
Brain tumor 17.3 22 1,371 747 53,352 2.31 (1.51–3.52) 0.000 3.69 (2.41–5.66) 0.000
Lung cancer 51.9 35 1,375 734 53,348 1.88 (1.34–2.63) 0.000 2.17 (1.53–3.08) 0.000
Breast cancer 17.3 19 1,450 750 53,273 1.62 (1.03–2.56) 0.038 2.34 (1.48–3.72) 0.000
Esophageal cancer 74.1 9 298 760 54,425 2.70 (1.40–5.20) 0.003 4.05 (2.09–7.84) 0.000
Gastric cancer 26.9 37 1,740 732 52,983 1.59 (1.14–2.21) 0.006 1.92 (1.37–2.67) 0.000
Colorectal cancer 29.6 39 1,885 730 52,838 1.61 (1.17–2.22) 0.004 1.82 (1.31–2.52) 0.000
Gynecologic cancer 28.3 16 1,108 753 53,615 2.24 (1.36–3.67) 0.001 3.34 (2.02–5.52) 0.000
Malignant lymphoma 95.2 93 1,824 676 52,899 9.34 (7.52–11.60) 0.000 8.39 (6.67–10.55) 0.000
Systemic lupus
erythematosus
53.7 38 1,039 731 53,684 10.45 (7.54–14.48) 0.000 4.11 (2.80–6.02) 0.000
Rheumatoid arthritis 30.0 110 6,604 659 48,119 2.38 (1.94–2.91) 0.000 2.03 (1.63–2.53) 0.000
Sjo ¨gren’s syndrome 44.7 16 1,131 753 53,592 3.45 (2.10–5.66) 0.000 1.30 (0.75–2.25) 0.350
Diabetes mellitus 24.9 273 15,517 496 39,206 2.14 (1.84–2.48) 0.000 2.38 (2.04–2.78) 0.000
Hypertension 27.4 282 15,693 487 39,030 1.64 (1.41–1.90) 0.000 1.93 (1.66–2.26) 0.000
Renal failure 56.3 73 2,504 696 52,219 3.30 (2.59–4.20) 0.000 2.21 (1.70–2.87) 0.000
Disc hernia 24.4 31 2,773 738 51,950 1.94 (1.35–2.78) 0.000 2.27 (1.58–3.26) 0.000
Cataract 23.0 198 18,049 571 36,674 0.64 (0.54–0.75) \0.0001 1.31 (0.91–1.27) 0.399
Depression 27.4 42 6,761 727 47,962 1.03 (0.75–1.41) 0.875 1.31 (0.95–1.80) 0.102
Female 29,494 396 29,098 373 25,625 0.81 (0.71–0.94) 0.004 0.90 (0.78–1.05) 0.184
Signiﬁcant associations were found between HZ and patients with one of 14 underlying diseases––brain tumor, lung cancer, breast cancer,
esophageal cancer, gastric cancer, colorectal cancer, gynecologic cancer, malignant lymphoma, SLE, RA, DM, hypertension, renal failure, and
disk hernia––compared to patients with none of these diseases in this cohort. Three underlying diseases (Sjo ¨gren’s syndrome, cataract,
depression) and female subjects showed no signiﬁcantly higher risk of HZ
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